News

Fierce Pharma34m
Vor Bio's surprise $4B revival deal for RemeGen's autoimmune drug triggers divergent stock reactions
For $45 million upfront, Vor Bio is gaining ex-China rights to RemeGen’s telitacicept, a first-in-class recombinant ...
Fierce Pharma59m
Emergent lands $62.4M upgrade to botulism antitoxin supply pact with US
A little less than a year after topping up its medical countermeasure contracts with Emergent BioSolutions, the federal ...